Liver Transplantation Clinical Trial
Official title:
Validation of Electrical Cardiometry in Resuscitation of Patients Undergoing Orthotopic Liver Transplantation
aim of our study to validate electrical cardiometry readings against same readings by transoesophageal echo. we will validate stroke volume (SV) readings stroke volume variation(SVV), index of contractility.
Induction of anaesthesia will be by using propofol (2mg.kg) IV, fentanyl (1-2μg. kg) IV and
atracurium (0.5 mg.kg) IV. Anaesthesia will be maintained with Sevoflurane adjusted between
1-2% in an air ⁄ oxygen mix (FiO2 0.6), fentanyl infusion at 1-2 μg.kg/h and atracurium
infusion at 0.5 mg.kg/ h. Mechanical ventilation will be provided by using a Dräger
anaesthesia machine (Dräger Primus®, Germany) using a tidal volume of 6-8 ml.kg with the
respiratory rate adjusted to maintain the PaCO2 between 4-4.6 kilopascal (kPa) and positive
end expiratory pressure (PEEP) of 5 cmH2O. All patients will be monitored for five lead ECG,
peripheral oxygen saturation, noninvasive and invasive arterial blood pressure, temperature,
end-tidal carbon dioxide tension, hourly urinary output, and central venous pressure (CVP). A
7-Fr triple lumen CVP catheter (Arrow International Inc, Reading, PA, USA) will be inserted
into the right internal jugular vein.
All patients will receive 6ml /kg/h Ringer acetate solution as a maintenance intraoperative
fluid. If SVV is more than 15%, the patient will be considered as fluid responder and will
receive a 250-ml bolus of albumin 5% to maintain SVV ≤15%. Blood transfusion will be given
based on a hemoglobin level (< 7 g/dl). Norepinephrine will be administered if the mean
arterial pressure was less than 70 mmHg. Epinephrine will be administered if mean arterial
blood pressure was less than 70 mm Hg and the cardiac index was less than 2.5 L/min/m2
despite sufficient volume infusion, to maintain a target cardiac index of 2.5-3.0 L/min/m2
Electrical cardiometry (EC) Examination:
1. ECG electrodes will be placed on the bare skin of patients in the following positions:
1. On the left neck below the ear;
2. Directly above the midpoint of the left clavicle;
3. Along the left mid-axillary line at the level of the xiphoid process;
4. Two inches caudal from the third electrode.
2. Patient characteristics of sex, age, height and weight will be entered into the monitor.
3. Clocks on the EC and trans esophageal echo (TEE) machine will be synchronized prior to
data collection.
4. The EC monitor will be programmed to capture moving averages of variables based on the
previous 10 cardiac cycles and to record those averages every10 s.
5. Only EC data with a signal quality index (SQI) of >70 will be included in the analysis.
Echo Examination:
1. A single LVOT diameter will be measured for each patient as the distance between the
inflection points at the base of the aortic valve cusps from the left ventricle long axis
view during systole.
2. Assuming a circular cross section, the LVOT area will be calculated from the LVOT
diameter as:
π X (LVOT diameter/ 2)2 = (LVOT diameter)2 X 0.785
3. Pulse wave Doppler sampling cursor will be placed in the middle of the LVOT immediately
proximal to the aortic valve in 5 chamber deep transgastric view.
4. The sonographer manually will trace the velocity-time envelope.
5. SV values will be identified for 10 cycles and averaged to obtain SV-Doppler max and
SV-Doppler min. The mean SV (SV-Doppler mean) will be calculated as (SV-Doppler max -
SV-Doppler min)/2.
6. SVV-Doppler will be calculated as (SV-Doppler max - SV-Doppler min)/SV-Doppler mean.
7. Peak aortic velocity, time to peak and mean acceleration will be calculated.
Mini Fluid challenge:
1. Mini fluid challenge will be done by 150 cc crystalloid over 1 min
2. 2 sets of measurement of SV and SVV will be obtained
1. The first set of measurement will be obtained before fluid challenge.
2. The second set will be obtained immediately after fluid challenge. Other data will
be recorded as;heart rate (HR), systolic BP, Diastolic BP, mean BP, CVP and pulse
pressure variation (PPV)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |